October 22, 2018
Spark Therapeutics Gene Therapy Research Webinar
Spark Therapeutics Gene TherapyA developing treatment that aims to fix, replace, or add genetic instructions. More Research Webinar Download an audio only version
October 8, 2018
Press Release: Spark Therapeutics Announces New Preclinical Data for Pompe Disease Gene Therapy
Spark Therapeutics Announces New Preclinical Data for Pompe DiseaseA rare genetic disease in which the body cannot properly break down glycogen, leading to buildup tha... More Gene TherapyA developing treatment that aims to fix, replace, or add genetic instructions. More Candidate Data from IND-enabling studies in three species support
September 25, 2018
Spark Therapeutics Gene Therapy Research Webinar
Webinar Details Title: Spark Therapeutics Gene TherapyA developing treatment that aims to fix, replace, or add genetic instructions. More Research Webinar Date: Tuesday, September 25, 2018 Speakers:Federico Mingozzi, PhD – Chief Scientific
September 16, 2018
AMDA Webinar: Spark Therapeutics Gene Therapy Research
SPARK THERAPEUTICS GENE THERAPYA developing treatment that aims to fix, replace, or add genetic instructions. More RESEARCH WEBINAR Please join the AMDA for a webinar focused on Spark Therapeutics and gene therapy
The AMDA is excited to announce a research grant opportunity for applicants who are involved in Pompe DiseaseA rare genetic disease in which the body cannot properly break down glycogen, leading to buildup tha... More research. This
September 10, 2018
Press Release: Amicus Announces Regulatory and Clinical Updates for AT-GAA in Pompe Disease
CRANBURY, N.J., Sept. 10, 2018—Amicus Therapeutics, a global biotechnology company focused on discovering, developing and delivering novel medicines for rare
Researchers from the Erasmus MC in Rotterdam, Netherlands, have succeeded in generating muscle cells from skin cells. This is significant
The AMDA is excited to announce a research grant opportunity for applicants who are involved in Pompe DiseaseA rare genetic disease in which the body cannot properly break down glycogen, leading to buildup tha... More research. This
CONCORD, Mass., July 11, 2017—Valerion Therapeutics, a clinical-stage biotechnology company that specializes in the development of therapies for orphan genetic
May 19, 2017
In Memory of Henri Termeer
he AMDA was saddened to learn of the sudden passing of Henri Termeer, former CEO of Genzyme. We have known

